Barclays PLC Buys 12,657 Shares of Iradimed Corporation (NASDAQ:IRMD)

Barclays PLC boosted its holdings in shares of Iradimed Corporation (NASDAQ:IRMD - Free Report) by 113.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,774 shares of the medical equipment provider's stock after acquiring an additional 12,657 shares during the quarter. Barclays PLC owned approximately 0.19% of Iradimed worth $1,196,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. raised its holdings in shares of Iradimed by 189.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 66,632 shares of the medical equipment provider's stock valued at $3,351,000 after purchasing an additional 43,635 shares in the last quarter. Oak Ridge Investments LLC acquired a new position in Iradimed during the third quarter worth $2,188,000. Eagle Asset Management Inc. bought a new position in Iradimed during the third quarter valued at about $1,239,000. Albert D Mason Inc. acquired a new stake in shares of Iradimed in the third quarter worth about $737,000. Finally, Algert Global LLC boosted its stake in shares of Iradimed by 84.1% during the 2nd quarter. Algert Global LLC now owns 26,774 shares of the medical equipment provider's stock worth $1,176,000 after acquiring an additional 12,227 shares in the last quarter. 92.34% of the stock is currently owned by institutional investors and hedge funds.

Iradimed Stock Performance

Shares of NASDAQ IRMD traded up $1.01 during mid-day trading on Tuesday, reaching $57.52. 29,729 shares of the company traded hands, compared to its average volume of 40,016. The company's fifty day moving average is $54.50 and its two-hundred day moving average is $49.80. Iradimed Corporation has a fifty-two week low of $40.18 and a fifty-two week high of $58.41. The stock has a market cap of $728.95 million, a PE ratio of 39.40 and a beta of 0.81.

Iradimed Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Friday, November 15th were paid a $0.15 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.60 dividend on an annualized basis and a yield of 1.04%. Iradimed's payout ratio is presently 41.10%.

Insider Buying and Selling

In other Iradimed news, CFO John Glenn sold 2,500 shares of Iradimed stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the transaction, the chief financial officer now directly owns 4,383 shares of the company's stock, valued at $237,470.94. The trade was a 36.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 37.10% of the company's stock.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.